546115-65-5

Basic information

• Product Name: 1-(3-BROMOPHENYL)CYCLOPROPANAMINE
• Synonyms: 1-(3-BROMOPHENYL)CYCLOPROPANAMINE;1-(3-BROMO-PHENYL)-CYCLOPROPYLAMINE;Cyclopropanamine, 1-(3-bromophenyl)-
• CAS NO: 546115-65-5
• Molecular Formula: C₉H₁₀BrN
• Molecular Weight: 212.09
• Mol File: 546115-65-5.mol

Chemical Properties

• Boiling Point: 273.843°C at 760 mmHg
• Flash Point: 119.416°C
• Appearance: /
• Density: 1.519g/cm³
• Vapor Pressure: 0.006mmHg at 25°C
• Refractive Index: 1.626
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 7.47±0.20(Predicted)
• CAS DataBase Reference: 1-(3-BROMOPHENYL)CYCLOPROPANAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-BROMOPHENYL)CYCLOPROPANAMINE(546115-65-5)
• EPA Substance Registry System: 1-(3-BROMOPHENYL)CYCLOPROPANAMINE(546115-65-5)

Safety Data

• Hazardous Substances Data: 546115-65-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
1-(3-BROMOPHENYL)CYCLOPROPANAMINE is used as a building block for the synthesis of various biologically active molecules due to its cyclopropane-containing structure and primary amine functionality. It serves as a starting material for the preparation of diverse cyclopropane-containing compounds with potential pharmacological properties, contributing to the discovery and development of new drugs.
Used in the Synthesis of Cyclopropane-Containing Compounds:
In the field of organic chemistry, 1-(3-BROMOPHENYL)CYCLOPROPANAMINE is used as a key intermediate for the synthesis of cyclopropane-containing compounds. Its unique structure allows for the creation of new molecules with potential applications in various therapeutic areas, including but not limited to pain management, anti-inflammatory treatments, and central nervous system disorders.
Used in Medicinal Chemistry:
1-(3-BROMOPHENYL)CYCLOPROPANAMINE is employed in medicinal chemistry as a valuable precursor for the design and synthesis of novel drug candidates. Its reactivity and structural features enable chemists to explore its potential in the development of new therapeutic agents with improved efficacy, selectivity, and safety profiles.

InChI:InChI=1/C9H10BrN/c10-8-3-1-2-7(6-8)9(11)4-5-9/h1-3,6H,4-5,11H2

Upstream product

• 6952-59-6 3-cyanobromobenzene 
• 925-90-6 ethylmagnesium bromide 
• 124276-95-5 1-(3-bromophenyl)cyclopropane-1-carboxylic acid 
• 597563-17-2 tert-butyl N-[1-(3-bromophenyl)cyclopropyl]carbamate 
• 597563-15-0 1-(3-bromophenyl)cyclopropan-1-amine hydrochloride 

Downstream Products

• 597563-16-1 C₂₄H₂₉BrF₂N₂O₃ 
• 597563-17-2 tert-butyl N-[1-(3-bromophenyl)cyclopropyl]carbamate 
• 1295298-15-5 1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid [1-(3-bromophenyl)cyclopropyl]amide 
• 1287220-78-3 tert-butyl 4-(4-(1-(3-bromophenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzoate 
• 1287220-79-4 tert-butyl 4-(4-(1-(3-(4-(tert-butoxycarbonylamino)butylamino)phenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzoate 

Relevant articles and documents

NOVEL POTASSIUM CHANNEL INHIBITORS

The present invention relates to novel compounds, pharmaceutical compositions comprising such compounds and their use for treating, alleviating or preventing diseases or disorders relating to the activity of potassium channels.

NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE

A compound of Formula I is provided: or pharmaceutically acceptable enantiomers, salts or solvates thereof. The 5 invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also 10 relates to a process for manufacturing compounds of Formula I.

MACROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AS BACE INHIBITORS

The invention relates to novel macrocyclic compounds of the formula in which R1, R3, V1, V2, X1, X2, Y, Z, Ar, AA and n are as defined in the specification, the number of ring atoms include

Substituted pteridines for the treatment of inflammatory diseases

The invention relates to new pteridines which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as

2-AMINO- AND 2-THIO-SUBSTITUTED 1,3-DIAMINOPROPANES

Disclosed are compounds of the formula: where variables Q, Z, X, R15, R2, R3, and Rc are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer’s disease and other diseases characterized by deposition of A beta peptide in a mammal.

PROCESS FOR PREPARING 5-(1, 3-OXAZOL-2-YL) BENZOIC ACID DERIVATIVES

Disclosed are compounds of formula III and a process to prepare a compound of formula III wherein R1, R2, R3 and R6 are defined herein, using a zinc chloride/optionally substituted oxazole adduct and an compound

A direct synthesis of 1-aryl- and 1-alkenylcyclopropylamines from aryl and alkenyl nitriles

The reaction of various aromatic nitriles with 1.1 equiv of Ti(Oi-Pr)4 and 2.2 equiv of EtMgBr followed by addition of a Lewis acid gave 1-aryl cyclopropylamines in 43-76% yields. Under similar conditions, conjugated alkene-nitriles afford 1-alkenylcyclopropylamines (42-65%).